Mismatch repair deficiencyMismatch repair proficiencyMicrosatellite stabilityAnti-programmed death-1 therapy has poor efficacy in mismatch repair-proficient (pMMR) colorectal cancers; however, its efficacy in pMMR gastric cancers remains undetermined. Here, we report the case of a patient with pMMR and ...
Mismatch repair deficiency (dMMR) cancers are highly sensitive to immunotherapy, but only account for a small fraction of cancer patients. How to increase immunotherapy efficacy on MMR-proficient (pMMR) cancer is still a major challenge. This study demonstrates that pyrithione zinc (PYZ), an FDA...
dMMR CRCs are notable for greater survivability, yet lack of benefit from fluoropyrimidine-based therapy in early-stage disease as compared to proficient DNA mismatch repair (pMMR) CRCs but are substantially lethal when metastatic. The surging interest in cancer immunotherapy, particularly checkpoint ...
four key genes: mutL homologue 1 (MLH1), postmeiotic segregation increased 2 (PMS2),mutS homologue 2(MSH2), and mutS 6 (MSH6). If one or more proteins are not expressed or are dysfunctional, the status is called dMMR; otherwise, the status is considered mismatch repair proficient (pMMR...
MSI-H/dMMR and microsatellite-stable (MSS)/proficient MMR (pMMR) GCs are distinct entities with widely differing genomic and immunogenic profiles and clinicopathologies (Fig.1). Fig. 1 Characteristics and potent treatment of MSI-H/dMMR GC. CIMP, CpG island methylation phenotype;TMBtumor mutationa...
Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance Anti-programmed death-1 therapy has poor efficacy in mismatch repair-proficient (pMMR) colorectal cancers; however, its efficacy in pMMR gastric cancers re... ...
Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance Anti-programmed death-1 therapy has poor efficacy in mismatch repair-proficient (pMMR) colorectal cancers; however, its efficacy in pMMR gastric cancers re... ...
Clinically, MSI tumors exhibit a favorable response to androgen deprivation therapy and moderate sensitivity to docetaxel compared to MMR-proficient tumors (pMMR). Notably, patients with MMRd or MSI prostate cancer demonstrate significant responses to the PD-1 inhibitor pembrolizumab. In their study of...
Tumor budding and a proficient mismatch repair (pMMR) status are considered adverse prognostic factors in colorectal cancer (CRC). The aim of this pilot study was to assess tumor budding in primary CRC with pMMR versus that with deficient mismatch repair (dMMR). Tumor budding was retrospectively...
Endometrioid histotype was statistically more frequent in deficient MMR (dMMR) tumors (73.3%), while non-endometrioid carcinomas in proficient (pMMR) cases (73.8%) (p<0.001). When analyzing the group of endometrioid and non-endometrioid carcinomas separately, only dMMR endometrioid cancers were ...